新型冠状病毒肺炎的药物治疗：靶向补体系统的潜在影响

Barkoff Courtney M, Mousa Shaker A

The Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, 1 Discovery Drive, Rensselaer, NY 12144, USA.

Biomedicines. 2020 Dec 24;9(1):11. doi: 10.3390/biomedicines9010011.

Coronavirus disease 2019 (COVID-19), a respiratory illness caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has claimed over one million lives worldwide since December 2019. The complement system, while a first-line immune defense against invading pathogens, has off-target effects that lead to increases in inflammation, tissue damage, and thrombosis; these are common, life-threatening complications seen in patients with COVID-19. This review explores the potential impact of complement activation in COVID-19 and possible treatments targeting the complement system.

2019冠状病毒病（COVID-19）是由严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染引起的一种呼吸道疾病，自2019年12月以来已在全球夺走了超过100万人的生命。补体系统虽然是抵御入侵病原体的一线免疫防御，但具有脱靶效应，会导致炎症、组织损伤和血栓形成增加；这些都是COVID-19患者常见的危及生命的并发症。本综述探讨了补体激活在COVID-19中的潜在影响以及针对补体系统的可能治疗方法。